This suggests that if a connection exists between semaglutide and the subjective experience of palpitations, it may be related to these documented heart rate changes rather than a separate mechanism
Research seems to indicate otherwise, as an obese individual typically has greater energy usage to maintain their increased BMI
Semaglutide, marketed under brands like Wegovy and Ozempic, works by mimicking the GLP-1 hormone to regulate appetite, slow digestion, and reduce cravings
Patients typically begin to see weight loss results within a few weeks of starting treatment with either Ozempic or Wegovy, with more significant and sustained weight reduction observed over several months (e.g., 68 weeks in clinical trials for Wegovy)
Your body weight fluctuates by 2 to 5 pounds on any given day based on water retention, sodium intake, bowel contents, glycogen stores, hormonal cycles, and dozens of other variables that have nothing to do with fat loss